Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies (vol 10, e003024, 2022)

被引：0
|
作者：
Michielin, O.
Lalani, A.
Robert, C.
机构：
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷 / 12期
关键词：
D O I：
10.1136/jitc-2021-003024corr1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 43 条
  • [31] Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer
    Naqash, Abdul Rafeh
    Mccallen, Justin D.
    Mi, Emma
    Iivanainen, Sanna
    Marie, Mona A.
    Gramenitskaya, Daria
    Clark, James
    Koivunen, Jussi Pekka
    Macherla, Shravanti
    Jonnalagadda, Sweta
    Polsani, Shanker
    Jiwani, Rahim Ali
    Hafiz, Maida
    Muzaffar, Mahvish
    Brunetti, Leonardo
    Stroud, Chipman R. G.
    Walker, Paul R.
    Wang, Kun
    Chung, Youngmin
    Ruppin, Eytan
    Lee, Se-Hoon
    Yang, Li, V
    Pinato, David J.
    Lee, Joo Sang
    Cortellini, Alessio
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (10)
  • [32] Impact of pretreatment body mass index on clinical outcomes in patients with metastatic renal cell carcinoma receiving first-line immune checkpoint inhibitor-based therapy: A systematic review and meta-analysis
    Lee, Kunwoo
    Yu, Jiwoong
    Song, Wan
    Sung, Hyun Hwan
    Jeon, Hwang Gyun
    Jeong, Byong Chang
    Seo, Seong Il
    Jeon, Seong Soo
    Kang, Minyong
    INVESTIGATIVE AND CLINICAL UROLOGY, 2024, 65 (05) : 423 - 434
  • [33] Association between KRAS variant status and outcomes with first-line immune checkpoint inhibitor-based therapy in patients with advanced non-small-cell lung cancer (vol 7, pg 937, 2021)
    Sun, L.
    Hsu, M.
    Cohen, R. B.
    Langer, C. J.
    Mamtani, R.
    Aggarwal, C.
    JAMA ONCOLOGY, 2021, 7 (07) : 1074 - 1074
  • [34] Clinical impact of p53 and AXL immunostaining on the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor mutant non-small cell lung cancer
    Morimoto, Kenji
    Yamada, Tadaaki
    Tokuda, Shinsaku
    Takayama, Koichi
    CANCER RESEARCH, 2023, 83 (07)
  • [35] Association of anticancer immune checkpoint inhibitors with patient-reported outcomes assessed in randomized clinical trials: a systematic review and meta-analysis (vol 5, e2226252, 2022)
    Conforti, Fabio
    JAMA NETWORK OPEN, 2022, 5 (12)
  • [36] Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor (vol 14, pg 1608, 2019)
    Kim, Y.
    Kim, C. H.
    Lee, H. Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : 2023 - 2023
  • [37] Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: a multicenter clinical study (vol 17, e0271907, 2022)
    Wakasakii, Takahiro
    Manako, Tomomi
    Yasumatsui, Ryuji
    Hara, Hirotaka
    Toh, Satoshi
    Masuda, Muneyuki
    Yamauchiid, Moriyasu
    Kuratomi, Yuichiro
    Nishimura, Emi
    Takeuchi, Toranoshin
    Matsuo, Mioko
    Jiromaru, Rina
    Hashimoto, Kazuki
    Komune, Noritaka
    Nakagawa, Takashi
    PLOS ONE, 2024, 19 (05):
  • [38] Clinical Effectiveness of Integrase Strand Transfer Inhibitor-Based Antiretroviral Regimens Among Adults With Human Immunodeficiency Virus: A Collaboration of Cohort Studies in the United States and Canada (vol 73, pg e1408, 2021)
    Lu, Haidong
    Cole, Stephen R.
    Westreich, Daniel
    Hudgens, Michael G.
    Adimora, Adaora A.
    Althoff, Keri N.
    Silverberg, Michael J.
    Buchacz, Kate
    Li, Jun
    Edwards, Jessie K.
    Rebeiro, Peter F.
    Lima, Viviane D.
    Marconi, Vincent C.
    Sterling, Timothy R.
    Horberg, Michael A.
    Gill, M. John
    Kitahata, Mari M.
    Eron, Joseph J.
    Moore, Richard D.
    CLINICAL INFECTIOUS DISEASES, 2022, 74 (04) : 755 - 755
  • [39] Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea (vol 34, pg 1098, 2011)
    Baik, G. H.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 34 (11-12) : 1358 - 1358
  • [40] Major adverse cardiac events (MACE) with immune checkpoint inhibitor (ICI)-based therapies for cancer: A pooled analysis of investigational clinical trials sponsored by the National Cancer Institute Cancer Therapy Evaluation Program (NCI-CTEP) in the United States and Canada
    Naqash, Abdul Rafeh
    Moey, Melissa
    Tan, Xiao-Wei Cherie
    Laharwal, Mehak Masood
    Hill, Vanessa
    Moka, Nagabhishek
    Finnigan, Shanda
    Murray, James H.
    Johnson, Douglas Buckner
    Moslehi, Javid J.
    Sharon, Elad
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345